Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
SB-02024 is an inhibitor of vacuolar protein sorting 34 (VPS34; IC50 = 5 nM).1 It selectively binds to VPS34 (Kd = 0.0011 µM) over eight other PI3K kinases (Kds = 1.2693->30 µM), mTOR (Kd = 1.0199 µM), a panel of 468 kinases at 1 µM, and an additional panel of 97 kinases at 1 µM.2 SB-02024 (0.7 µM) inhibits autophagic flux in H1299 cells. In vivo, SB-02024 (20 mg/kg) enhances increases in survival when used in combination with an antibody targeting programmed cell death protein 1 (PD-1) or PD-1 ligand (PD-L1) in B16/F10 murine melanoma and CT26 murine colorectal cancer models.3 SB-02024 (20 mg/kg) also enhances increases in survival and decreases in tumor volume when used in combination with the STING agonist ADU-S100 (Item No. 27901) in a B16/F10 murine melanoma model.1
WARNING This product is not for human or veterinary use.
1. Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-
2. Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib. Cancer Lett. 435, 32-43 (2018).
3. Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-